Gradient Bioconvergence
Gradient Bioconvergence provides patient-derived organoids to model cancer and test treatments. It maintains a large PDO repository and develops co-culture systems that pair autologous immune cells and cancer-associated fibroblasts with organoids. The company leverages genomic, transcriptomic and drug-response data, an AI-driven discovery engine, and CRISPR-enabled PDO platforms to identify novel oncology targets. In addition, it is developing brain organoids from human iPSCs to support drug evaluation and regenerative medicine research. The business targets pharma and biotech customers globally as a data- and platform-enabled B2B Biotech tool provider.
Gradient Bioconvergence
Gradient Bioconvergence provides patient-derived organoids to model cancer and test treatments. It maintains a large PDO repository and develops co-culture systems that pair autologous immune cells and cancer-associated fibroblasts with organoids. The company leverages genomic, transcriptomic and drug-response data, an AI-driven discovery engine, and CRISPR-enabled PDO platforms to identify novel oncology targets. In addition, it is developing brain organoids from human iPSCs to support drug evaluation and regenerative medicine research. The business targets pharma and biotech customers globally as a data- and platform-enabled B2B Biotech tool provider.